nach oben

Erschienen in:

01.07.2019 | Original Paper

Long- and short-term association of low-grade systemic inflammation with cardiovascular mortality in the LURIC study

verfasst von: Anna-Isabelle Kälsch, Hubert Scharnagl, Marcus E. Kleber, Christian Windpassinger, Wolfgang Sattler, Jan Leipe, Bernhard K. Krämer, Winfried März, Ernst Malle

Erschienen in: Clinical Research in Cardiology | Ausgabe 3/2020

Einloggen, um Zugang zu erhalten

Abstract

Background

The present study aimed to evaluate biomarkers representing low-grade systemic inflammation and their association with cardiovascular mortality in the Ludwigshafen Risk and Cardiovascular Health (LURIC) study.

Methods

The included 3134 consecutive patients underwent coronary angiography between June 1997 and May 2001 with a median follow-up of 9.9 years. Plasma levels of IL-6, and acute-phase reactants serum amyloid A (SAA) and C-reactive protein (CRP) were measured. SAA and IL-6 polymorphisms were genotyped.

Results

During a median observation time of 9.9 years, 949 deaths (30.3%) occurred, of these 597 (19.2%) died from cardiovascular causes. High plasma levels of IL-6, CRP and SAA were associated with unstable CAD, as well as established risk factors including type 2 diabetes mellitus, smoking, low glomerular filtration rate, low TGs and low HDL-C. After adjusting for established cardiovascular risk markers and the other two inflammatory markers, SAA was found to be an independent risk factor for cardiovascular mortality after a short-term follow-up (6 months–1 year) with a HR per SD of 1.41. IL-6 was identified as an independent risk factor for long-term follow-up (3, 5, and 9.9 years) with HRs per SD of 1.21, 1.22 and 1.18. CRP lost significance after adjustment. Although 6 out of 27 SAA SNPs were significantly associated with SAA plasma concentrations, the genetic risk score was not associated with cardiovascular mortality.

Conclusions

The present findings from the large, prospective LURIC cohort underline the importance of inflammation in CAD and the prognostic relevance of inflammatory biomarkers that independently predict cardiovascular mortality.

Graphic abstract

Nur mit Berechtigung zugänglich

Roth GA, Johnson C, Abajobir A, Abd-Allah F, Abera SF, Abyu G, Ahmed M, Aksut B, Alam T, Alam K, Alla F, Alvis-Guzman N, Amrock S, Ansari H, Arnlov J, Asayesh H, Atey TM, Avila-Burgos L, Awasthi A, Banerjee A, Barac A, Barnighausen T, Barregard L, Bedi N, Belay Ketema E, Bennett D, Berhe G, Bhutta Z, Bitew S, Carapetis J, Carrero JJ, Malta DC, Castaneda-Orjuela CA, Castillo-Rivas J, Catala-Lopez F, Choi JY, Christensen H, Cirillo M, Cooper L Jr, Criqui M, Cundiff D, Damasceno A, Dandona L, Dandona R, Davletov K, Dharmaratne S, Dorairaj P, Dubey M, Ehrenkranz R, El Sayed Zaki M, Faraon EJA, Esteghamati A, Farid T, Farvid M, Feigin V, Ding EL, Fowkes G, Gebrehiwot T, Gillum R, Gold A, Gona P, Gupta R, Habtewold TD, Hafezi-Nejad N, Hailu T, Hailu GB, Hankey G, Hassen HY, Abate KH, Havmoeller R, Hay SI, Horino M, Hotez PJ, Jacobsen K, James S, Javanbakht M, Jeemon P, John D, Jonas J, Kalkonde Y, Karimkhani C, Kasaeian A, Khader Y, Khan A, Khang YH, Khera S, Khoja AT, Khubchandani J, Kim D, Kolte D, Kosen S, Krohn KJ, Kumar GA, Kwan GF, Lal DK, Larsson A, Linn S, Lopez A, Lotufo PA, El Razek HMA, Malekzadeh R, Mazidi M, Meier T, Meles KG, Mensah G, Meretoja A, Mezgebe H, Miller T, Mirrakhimov E, Mohammed S, Moran AE, Musa KI, Narula J, Neal B, Ngalesoni F, Nguyen G, Obermeyer CM, Owolabi M, Patton G, Pedro J, Qato D, Qorbani M, Rahimi K, Rai RK, Rawaf S, Ribeiro A, Safiri S, Salomon JA, Santos I, Santric Milicevic M, Sartorius B, Schutte A, Sepanlou S, Shaikh MA, Shin MJ, Shishehbor M, Shore H, Silva DAS, Sobngwi E, Stranges S, Swaminathan S, Tabares-Seisdedos R, Tadele Atnafu N, Tesfay F, Thakur JS, Thrift A, Topor-Madry R, Truelsen T, Tyrovolas S, Ukwaja KN, Uthman O, Vasankari T, Vlassov V, Vollset SE, Wakayo T, Watkins D, Weintraub R, Werdecker A, Westerman R, Wiysonge CS, Wolfe C, Workicho A, Xu G, Yano Y, Yip P, Yonemoto N, Younis M, Yu C, Vos T, Naghavi M, Murray C (2017) Global, regional, and national burden of cardiovascular diseases for 10 causes, 1990 to 2015. J Am Coll Cardiol 70(1):1–25. https://doi.org/10.1016/j.jacc.2017.04.052 CrossRefPubMedPubMedCentral

Libby P (2012) Inflammation in atherosclerosis. Arterioscler Thromb Vasc Biol 32(9):2045–2051. https://doi.org/10.1161/ATVBAHA.108.179705 CrossRefPubMedPubMedCentral

Schunkert H, von Scheidt M, Kessler T, Stiller B, Zeng L, Vilne B (2018) Genetics of coronary artery disease in the light of genome-wide association studies. Clin Res Cardiol 107(Suppl 2):2–9. https://doi.org/10.1007/s00392-018-1324-1 CrossRefPubMed

Chung CP, Oeser A, Raggi P, Gebretsadik T, Shintani AK, Sokka T, Pincus T, Avalos I, Stein CM (2005) Increased coronary-artery atherosclerosis in rheumatoid arthritis: relationship to disease duration and cardiovascular risk factors. Arthritis Rheum 52(10):3045–3053. https://doi.org/10.1002/art.21288 CrossRefPubMed

Ward MM (1999) Premature morbidity from cardiovascular and cerebrovascular diseases in women with systemic lupus erythematosus. Arthritis Rheum 42(2):338–346. https://doi.org/10.1002/1529-0131(199902)42:2%3c338:AID-ANR17%3e3.0.CO;2-U CrossRefPubMed

Hansson GK, Robertson AK, Soderberg-Naucler C (2006) Inflammation and atherosclerosis. Annu Rev Pathol 1:297–329. https://doi.org/10.1146/annurev.pathol.1.110304.100100 CrossRefPubMed

Maggio M, Guralnik JM, Longo DL, Ferrucci L (2006) Interleukin-6 in aging and chronic disease: a magnificent pathway. J Gerontol A Biol Sci Med Sci 61(6):575–584CrossRefPubMed

Ziegler I, Cajander S, Rasmussen G, Ennefors T, Molling P, Stralin K (2019) High nuc DNA load in whole blood is associated with sepsis, mortality and immune dysregulation in Staphylococcus aureus bacteraemia. Infect Dis (Lond) 51:216–226. https://doi.org/10.1080/23744235.2018.1562205 CrossRef

Ferrante G, Condorelli G (2019) Interleukin-6 trans-signalling and risk of future cardiovascular events: a new avenue for atheroprotection? Cardiovasc Res 115(1):8–9. https://doi.org/10.1093/cvr/cvy233 CrossRefPubMed

10.

Schuett H, Oestreich R, Waetzig GH, Annema W, Luchtefeld M, Hillmer A, Bavendiek U, von Felden J, Divchev D, Kempf T, Wollert KC, Seegert D, Rose-John S, Tietge UJ, Schieffer B, Grote K (2012) Transsignaling of interleukin-6 crucially contributes to atherosclerosis in mice. Arterioscler Thromb Vasc Biol 32(2):281–290. https://doi.org/10.1161/ATVBAHA.111.229435 CrossRefPubMed

11.

Ridker PM (2017) Canakinumab for residual inflammatory risk. Eur Heart J 38(48):3545–3548. https://doi.org/10.1093/eurheartj/ehx723 CrossRefPubMed

12.

Macy EM, Hayes TE, Tracy RP (1997) Variability in the measurement of C-reactive protein in healthy subjects: implications for reference intervals and epidemiological applications. Clin Chem 43(1):52–58CrossRefPubMed

13.

Inoue T, Kato T, Uchida T, Sakuma M, Nakajima A, Shibazaki M, Imoto Y, Saito M, Hashimoto S, Hikichi Y, Node K (2005) Local release of C-reactive protein from vulnerable plaque or coronary arterial wall injured by stenting. J Am Coll Cardiol 46(2):239–245. https://doi.org/10.1016/j.jacc.2005.04.029 CrossRefPubMed

14.

Volanakis JE (1982) Complement activation by C-reactive protein complexes. Ann NY Acad Sci 389:235–250CrossRefPubMed

15.

Koenig W (2013) High-sensitivity C-reactive protein and atherosclerotic disease: from improved risk prediction to risk-guided therapy. Int J Cardiol 168(6):5126–5134. https://doi.org/10.1016/j.ijcard.2013.07.113 CrossRefPubMed

16.

Malle E, De Beer FC (1996) Human serum amyloid A (SAA) protein: a prominent acute-phase reactant for clinical practice. Eur J Clin Invest 26(6):427–435CrossRefPubMed

17.

Ye RD, Sun L (2015) Emerging functions of serum amyloid A in inflammation. J Leukoc Biol 98(6):923–929. https://doi.org/10.1189/jlb.3VMR0315-080R CrossRefPubMedPubMedCentral

18.

King VL, Thompson J, Tannock LR (2011) Serum amyloid A in atherosclerosis. Curr Opin Lipidol 22(4):302–307. https://doi.org/10.1097/MOL.0b013e3283488c39 CrossRefPubMed

19.

Getz GS, Krishack PA, Reardon CA (2016) Serum amyloid A and atherosclerosis. Curr Opin Lipidol 27(5):531–535. https://doi.org/10.1097/MOL.0000000000000331 CrossRefPubMed

20.

Kontush A, Chapman MJ (2006) Functionally defective high-density lipoprotein: a new therapeutic target at the crossroads of dyslipidemia, inflammation, and atherosclerosis. Pharmacol Rev 58(3):342–374. https://doi.org/10.1124/pr.58.3.1 CrossRefPubMed

21.

Zewinger S, Drechsler C, Kleber ME, Dressel A, Riffel J, Triem S, Lehmann M, Kopecky C, Saemann MD, Lepper PM, Silbernagel G, Scharnagl H, Ritsch A, Thorand B, de las Heras-Gala T, Wagenpfeil S, Koenig W, Peters A, Laufs U, Wanner C, Fliser D, Speer T, Marz W (2015) Serum amyloid A: high-density lipoproteins interaction and cardiovascular risk. Eur Heart J 36(43):3007–3016. https://doi.org/10.1093/eurheartj/ehv352 CrossRefPubMed

22.

Navab M, Anantharamaiah GM, Reddy ST, Van Lenten BJ, Ansell BJ, Fogelman AM (2006) Mechanisms of disease: proatherogenic HDL—an evolving field. Nat Clin Pract Endocrinol Metab 2(9):504–511. https://doi.org/10.1038/ncpendmet0245 CrossRefPubMed

23.

Artl A, Marsche G, Lestavel S, Sattler W, Malle E (2000) Role of serum amyloid A during metabolism of acute-phase HDL by macrophages. Arterioscler Thromb Vasc Biol 20(3):763–772CrossRefPubMed

24.

Artl A, Marsche G, Pussinen P, Knipping G, Sattler W, Malle E (2002) Impaired capacity of acute-phase high density lipoprotein particles to deliver cholesteryl ester to the human HUH-7 hepatoma cell line. Int J Biochem Cell Biol 34(4):370–381CrossRefPubMed

25.

Song C, Hsu K, Yamen E, Yan W, Fock J, Witting PK, Geczy CL, Freedman SB (2009) Serum amyloid A induction of cytokines in monocytes/macrophages and lymphocytes. Atherosclerosis 207(2):374–383. https://doi.org/10.1016/j.atherosclerosis.2009.05.007 CrossRefPubMed

26.

Dong Z, Wu T, Qin W, An C, Wang Z, Zhang M, Zhang Y, Zhang C, An F (2011) Serum amyloid A directly accelerates the progression of atherosclerosis in apolipoprotein E-deficient mice. Mol Med 17(11–12):1357–1364. https://doi.org/10.2119/molmed.2011.00186 CrossRefPubMedPubMedCentral

27.

Thompson JC, Jayne C, Thompson J, Wilson PG, Yoder MH, Webb N, Tannock LR (2015) A brief elevation of serum amyloid A is sufficient to increase atherosclerosis. J Lipid Res 56(2):286–293. https://doi.org/10.1194/jlr.M054015 CrossRefPubMedPubMedCentral

28.

Biasucci LM, Liuzzo G, Fantuzzi G, Caligiuri G, Rebuzzi AG, Ginnetti F, Dinarello CA, Maseri A (1999) Increasing levels of interleukin (IL)-1Ra and IL-6 during the first 2 days of hospitalization in unstable angina are associated with increased risk of in-hospital coronary events. Circulation 99(16):2079–2084CrossRefPubMed

29.

Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hennekens CH (1997) Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med 336(14):973–979. https://doi.org/10.1056/NEJM199704033361401 CrossRefPubMed

30.

Winkelmann BR, Marz W, Boehm BO, Zotz R, Hager J, Hellstern P, Senges J, Group LS (2001) Rationale and design of the LURIC study—a resource for functional genomics, pharmacogenomics and long-term prognosis of cardiovascular disease. Pharmacogenomics 2(1 Suppl 1):S1–73. https://doi.org/10.1517/14622416.2.1.S1 CrossRefPubMed

31.

Austen WG, Edwards JE, Frye RL, Gensini GG, Gott VL, Griffith LS, McGoon DC, Murphy ML, Roe BB (1975) A reporting system on patients evaluated for coronary artery disease. Report of the Ad Hoc Committee for Grading of Coronary Artery Disease, Council on Cardiovascular Surgery, American Heart Association. Circulation 51(4 Suppl):5–40CrossRefPubMed

32.

Friesinger GC, Page EE, Ross RS (1970) Prognostic significance of coronary arteriography. Trans Assoc Am Physicians 83:78–92PubMed

33.

Stevens LA, Schmid CH, Zhang YL, Coresh J, Manzi J, Landis R, Bakoush O, Contreras G, Genuth S, Klintmalm GB, Poggio E, Rossing P, Rule AD, Weir MR, Kusek J, Greene T, Levey AS (2010) Development and validation of GFR-estimating equations using diabetes, transplant and weight. Nephrol Dial Transpl 25(2):449–457. https://doi.org/10.1093/ndt/gfp510 CrossRef

34.

Grammer TB, Marz W, Renner W, Bohm BO, Hoffmann MM (2009) C-reactive protein genotypes associated with circulating C-reactive protein but not with angiographic coronary artery disease: the LURIC study. Eur Heart J 30(2):170–182. https://doi.org/10.1093/eurheartj/ehn191 CrossRefPubMed

35.

Zamani P, Schwartz GG, Olsson AG, Rifai N, Bao W, Libby P, Ganz P, Kinlay S, Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering Study I (2013) Inflammatory biomarkers, death, and recurrent nonfatal coronary events after an acute coronary syndrome in the MIRACL study. J Am Heart Assoc 2(1):e003103. https://doi.org/10.1161/JAHA.112.003103 CrossRefPubMedPubMedCentral

36.

Zairis MN, Adamopoulou EN, Manousakis SJ, Lyras AG, Bibis GP, Ampartzidou OS, Apostolatos CS, Anastassiadis FA, Hatzisavvas JJ, Argyrakis SK, Foussas SG, Biomarkers of I, Outcome in Acute Coronary Syndromes I (2007) The impact of hs C-reactive protein and other inflammatory biomarkers on long-term cardiovascular mortality in patients with acute coronary syndromes. Atherosclerosis 194(2):397–402. https://doi.org/10.1016/j.atherosclerosis.2006.08.008 CrossRefPubMed

37.

Held C, White HD, Stewart RAH, Budaj A, Cannon CP, Hochman JS, Koenig W, Siegbahn A, Steg PG, Soffer J, Weaver WD, Ostlund O, Wallentin L, Investigators S (2017) Inflammatory biomarkers interleukin-6 and C-reactive protein and outcomes in stable coronary heart disease: experiences from the STABILITY (Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy) Trial. J Am Heart Assoc. https://doi.org/10.1161/JAHA.116.005077 CrossRefPubMedPubMedCentral

38.

Simic-Ogrizovic S, Dopsaj V, Bogavac-Stanojevic N, Obradovic I, Stosovic M, Radovic M (2009) Serum amyloid-A rather than C-reactive protein is a better predictor of mortality in hemodialysis patients. Tohoku J Exp Med 219(2):121–127CrossRefPubMed

39.

Nissen SE, Tuzcu EM, Schoenhagen P, Crowe T, Sasiela WJ, Tsai J, Orazem J, Magorien RD, O’Shaughnessy C, Ganz P, Reversal of Atherosclerosis with Aggressive Lipid Lowering I (2005) Statin therapy, LDL cholesterol, C-reactive protein, and coronary artery disease. N Engl J Med 352(1):29–38. https://doi.org/10.1056/NEJMoa042000 CrossRefPubMed

40.

Ridker PM, Danielson E, Fonseca FA, Genest J, Gotto AM Jr, Kastelein JJ, Koenig W, Libby P, Lorenzatti AJ, Macfadyen JG, Nordestgaard BG, Shepherd J, Willerson JT, Glynn RJ, Group JTS (2009) Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trial. Lancet 373(670):1175–1182. https://doi.org/10.1016/S0140-6736(09)60447-5 CrossRefPubMed

41.

Collaboration CRPCHDG, Wensley F, Gao P, Burgess S, Kaptoge S, Di Angelantonio E, Shah T, Engert JC, Clarke R, Davey-Smith G, Nordestgaard BG, Saleheen D, Samani NJ, Sandhu M, Anand S, Pepys MB, Smeeth L, Whittaker J, Casas JP, Thompson SG, Hingorani AD, Danesh J (2011) Association between C reactive protein and coronary heart disease: mendelian randomisation analysis based on individual participant data. BMJ 342:d548. https://doi.org/10.1136/bmj.d548 CrossRef

42.

Ridker PM, Everett BM, Thuren T, MacFadyen JG, Chang WH, Ballantyne C, Fonseca F, Nicolau J, Koenig W, Anker SD, Kastelein JJP, Cornel JH, Pais P, Pella D, Genest J, Cifkova R, Lorenzatti A, Forster T, Kobalava Z, Vida-Simiti L, Flather M, Shimokawa H, Ogawa H, Dellborg M, Rossi PRF, Troquay RPT, Libby P, Glynn RJ (2017) Antiinflammatory therapy with canakinumab for atherosclerotic disease. N Engl J Med 377(12):1119–1131. https://doi.org/10.1056/NEJMoa1707914 CrossRefPubMed

43.

Ridker PM, Libby P, MacFadyen JG, Thuren T, Ballantyne C, Fonseca F, Koenig W, Shimokawa H, Everett BM, Glynn RJ (2018) Modulation of the interleukin-6 signalling pathway and incidence rates of atherosclerotic events and all-cause mortality: analyses from the Canakinumab Anti-Inflammatory Thrombosis Outcomes Study (CANTOS). Eur Heart J 39(38):3499–3507. https://doi.org/10.1093/eurheartj/ehy310 CrossRefPubMed

44.

Groot HE, Al Ali L, van der Horst ICC, Schurer RAJ, van der Werf HW, Lipsic E, van Veldhuisen DJ, Karper JC, van der Harst P (2018) Plasma interleukin 6 levels are associated with cardiac function after ST-elevation myocardial infarction. Clin Res Cardiol. https://doi.org/10.1007/s00392-018-1387-z CrossRefPubMedPubMedCentral

45.

Martinez GJ, Robertson S, Barraclough J, Xia Q, Mallat Z, Bursill C, Celermajer DS, Patel S (2015) Colchicine acutely suppresses local cardiac production of inflammatory cytokines in patients with an acute coronary syndrome. J Am Heart Assoc 4(8):e002128. https://doi.org/10.1161/JAHA.115.002128 CrossRefPubMedPubMedCentral

46.

Thompson PL, Nidorf SM (2018) Colchicine: an affordable anti-inflammatory agent for atherosclerosis. Curr Opin Lipidol 29(6):467–473. https://doi.org/10.1097/MOL.0000000000000552 CrossRefPubMed

47.

Yin YW, Li JC, Zhang M, Wang JZ, Li BH, Liu Y, Liao SQ, Zhang MJ, Gao CY, Zhang LL (2013) Influence of interleukin-6 gene -174G > C polymorphism on development of atherosclerosis: a meta-analysis of 50 studies involving 33,514 subjects. Gene 529(1):94–103. https://doi.org/10.1016/j.gene.2013.07.074 CrossRefPubMed

48.

Carty CL, Heagerty P, Heckbert SR, Enquobahrie DA, Jarvik GP, Davis S, Tracy RP, Reiner AP (2009) Association of genetic variation in serum amyloid-A with cardiovascular disease and interactions with IL6, IL1RN, IL1beta and TNF genes in the Cardiovascular Health Study. J Atheroscler Thromb 16(4):419–430CrossRefPubMed

49.

Casas JP, Shah T, Cooper J, Hawe E, McMahon AD, Gaffney D, Packard CJ, O’Reilly DS, Juhan-Vague I, Yudkin JS, Tremoli E, Margaglione M, Di Minno G, Hamsten A, Kooistra T, Stephens JW, Hurel SJ, Livingstone S, Colhoun HM, Miller GJ, Bautista LE, Meade T, Sattar N, Humphries SE, Hingorani AD (2006) Insight into the nature of the CRP-coronary event association using Mendelian randomization. Int J Epidemiol 35(4):922–931. https://doi.org/10.1093/ije/dyl041 CrossRefPubMed

Titel: Long- and short-term association of low-grade systemic inflammation with cardiovascular mortality in the LURIC study
verfasst von: Anna-Isabelle Kälsch
Hubert Scharnagl
Marcus E. Kleber
Christian Windpassinger
Wolfgang Sattler
Jan Leipe
Bernhard K. Krämer
Winfried März
Ernst Malle
Publikationsdatum: 01.07.2019
Verlag: Springer Berlin Heidelberg
Erschienen in: Clinical Research in Cardiology / Ausgabe 3/2020
Print ISSN: 1861-0684
Elektronische ISSN: 1861-0692
DOI: https://doi.org/10.1007/s00392-019-01516-9

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Long- and short-term association of low-grade systemic inflammation with cardiovascular mortality in the LURIC study

Abstract

Background

Methods

Results

Conclusions

Graphic abstract

Neu im Fachgebiet Kardiologie

Ist Fasten vor Koronarinterventionen wirklich nötig?

PET kann infarktgefährdete Koronararterien entdecken

GLP-1-Agonist Semaglutid wirkt kardio- und nephroprotektiv

Nach Herzinfarkt mit Typ-1-Diabetes schlechtere Karten als mit Typ 2?

Update Kardiologie

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Abstract

Background

Methods

Results

Conclusions

Graphic abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2020

Culprit vessel-related myocardial mechanics and prognostic implications following acute myocardial infarction

Myeloperoxidase in atrial fibrillation: association with progression, origin and influence of renin–angiotensin system antagonists

Comparison between treatment of “established” versus complex “off-label” coronary lesions with Absorb® bioresorbable scaffold implantation: results from the GABI-R® registry

Association of heart failure duration with clinical prognosis in advanced heart failure

Transvascular transcatheter aortic valve implantation in 2017

Predictors of transportation delay in patients with suspected ST-elevation-myocardial infarction in the VIENNA-STEMI network

Neu im Fachgebiet Kardiologie

Ist Fasten vor Koronarinterventionen wirklich nötig?

PET kann infarktgefährdete Koronararterien entdecken

GLP-1-Agonist Semaglutid wirkt kardio- und nephroprotektiv

Nach Herzinfarkt mit Typ-1-Diabetes schlechtere Karten als mit Typ 2?

Update Kardiologie